

**CONSOLIDATED INDEPENDENT AUDITORS REPORT**

**TO THE MEMBER OF  
CHANDAN HEALTHCARE LIMITED**

**Report on the Audit of Consolidated Financial Statements as at 31<sup>st</sup> March, 2023.**

We have audited the Consolidated financial statements of **CHANDAN HEALTHCARE LIMITED**, which comprise the balance sheet as at 31st March 2023, and the statement of Profit and Loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information. Which we have signed under reference to this report.

In our opinion and to the best of our information and according to the explanations given to us, the a fore said Consolidated financial statements give the information required by the **Companies Act, 2013** in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31 2023, the Profit for the year ended on that date.

**Basis for Opinion**

We conducted our audit of Consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of financial statements under the provisions of the Companies Act, 2013 and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on consolidated financial Statements.



📍 : Head Office: - A-40, 1<sup>st</sup> Floor, Lower-B, 10<sup>th</sup> Block, Unit No. 1033, Sector 62, Noida-201305.  
Branch Office: - SJ Plaza – 8<sup>th</sup> Floor, Office No 824, Marve Road, Above NM Medical Near Nutan School, Ch S V Road, Malad (W), Mumbai - 400044.  
Branch Office: - A-504, Ansari Chamber, 1, Bhikai Cama Place, New Delhi-110060.  
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436434, CA Manoj Modi: 9022139211  
✉ : [saurabh@msnt.in](mailto:saurabh@msnt.in), [navodit@msnt.in](mailto:navodit@msnt.in), [manoj@msnt.in](mailto:manoj@msnt.in)



- Obtain an understanding of Internal Control relevant to Audit in order to design Audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control system.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decision of the reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) Planning the Scope of our audit work and in evaluating the result of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial Statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



## Report on Other Legal and Regulatory Requirements

1. As required by the Companies(Auditor's Report)Order,2020, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c. The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d. In our opinion, the aforesaid Consolidated financial statements comply with the Accounting Standards specified under Section133 of the Act, read with Rule 7 of the **Companies (Accounting Standards) Rules, 2021**.
- e. On the basis of the written representations received from the directors as on 31<sup>st</sup> March 2023, taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2023, from being appointed as a director in terms of Section 164(2) of the Act.
- f. In our opinion, the provision of section 143(3)(i) with regard to the opinion on internal financial controls with reference to financial statements and the operating effectiveness of such controls is applicable to the company.

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the **Companies (Audit and Auditors) Rules, 2014**, in our opinion and to the best of our information and according to the explanations given to us:

- The Company does not have any pending litigations in financial statements, which would impact on its financial position.
- The Company does not have any long-term contracts, including derivative contracts for which there were any material foreseeable losses.
- There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share




premium or any other sources or kind of funds) by the company to or in any other person(s) or entity (ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

- (ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.

- The company has not declared or paid any dividend during the year

4. With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.

**For MSNT & ASSOCIATES LLP**  
**Chartered Accountants**  
**Firm Registration No.018542C/C400322**

  
**Navodit Tyagi**  
**Partner**  
**Membership No. -533375**  
**UDIN No: 23533375BGXPWO6826**  
**Place: Noida**  
**Date: 02/09/2023**



**Annexure A to the Independent Auditor's report to the Shareholder**

To the Independent Auditors' Report on the Consolidated Financial Statement of  
CHANDAN HEALTHCARE LIMITED

In terms of the information and explanations sought by us and given by the company  
and the books of account and records examined by us in the normal course of audit  
and to the best of our knowledge and belief, we state that:

**(xxii) In Respect of Qualification or Adverse remarks of Auditors on Group  
Companies:**

There are no qualifications or adverse remarks by the respective auditors in the  
Companies (Auditors Report) Order (CARO) reports of the companies included  
in the consolidated financial statements. Accordingly, the requirement to report  
on clause 3(xxii) of the Order is not applicable to the Holding Company.

**For MSNT & ASSOCIATES LLP**

**Chartered Accountants**

**Firm Registration No.018542C/C400322**

  
**Navodit Tyagi**

**Partner**

**Membership No.-533375**

**UDIN No: 23533375BGXPWO6826**

**Place: Noida**

**Date: 02/09/2023**





### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For MSNT & ASSOCIATES LLP**

**Chartered Accountants**

**Firm Registration No.018542C/C400322**

**Navodit Tyagi**

**Partner**

**Membership No.-533375**

**UDIN No: 23533375BGXPWO6826**

**Place: Noida**

**Date: 02/09/2023**





**Consolidated Financial Statements of Chandan HealthCare Limited  
And its Subsidiaries Indra Diagnostic Centre & Blood Bank Limited, Chandan Diagnostic Limited and Chandan Pharmacy Limited**  
Corp. off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow 226021  
Reg Off. Add.: A-15, Vivek Vihar, Phase-1, Delhi 110095  
CIN: U85110DL2003PLC308206  
Consolidated Balance Sheet as at 31-Mar-2023

			In ₹ (LAKH)	
Particulars		Note No.	as at 31-Mar-2023	as at 31-Mar-2022
<b>I. EQUITY AND LIABILITIES</b>				
1	Shareholders' Funds		<b>2,489.94</b>	<b>2,614.80</b>
	(a) Share Capital	4	2,000.00	2,000.00
	(b) Reserves and Surplus	5	489.9	614.80
	(c) Money Received Against Share Warrants			
2	Minority Interest		41.76	15.02
			<b>41.76</b>	<b>15.02</b>
3	Non-Current Liabilities		<b>937.06</b>	<b>785.55</b>
	(a) Long-Term Borrowings	6	789.04	668.72
	(b) Deferred Tax Liabilities (Net)		148.01	116.84
	(c) Other Long-Term Liabilities			
	(d) Long-Term Provisions			
4	Current Liabilities		<b>5,945.31</b>	<b>4,205.44</b>
	(a) Short-Term Borrowings	7	1,561.97	869.57
	(b) Trade Payables	8		
	(i) Total outstanding dues of micro and small enterprises		475.73	130.53
	(ii) Total outstanding dues of other than micro and small enterprises		319.56	1,504.56
	(c) Other Current Liabilities	9	3,270.27	1,285.30
	(d) Short-Term Provisions	10	367.78	334.88
	<b>Total</b>		<b>9,414.07</b>	<b>7,620.81</b>
<b>II. ASSETS</b>				
1	Non-Current Assets		<b>4,430.59</b>	<b>3,801.16</b>
	(a) (i) Property, Plant and Equipment	11	2,812.33	2,493.34
	(ii) Capital Work-in-Progress			
	(iii) Intangible Assets			
	(iv) Intangible Assets under Development			
	(b) Non-Current Investments	12	708.65	7,036.64
	(c) Deferred Tax Assets (Net)		8.59	8.59
	(d) Long-Term Loans and Advances	13	835.64	207.82
	(e) Other Non-Current Assets	14	64.35	54.78
2	Current Assets		<b>4,983.48</b>	<b>3,819.65</b>
	(a) Current Investments			
	(b) Inventories	15	987.17	656.03
	(c) Trade Receivables	16	1,397.00	1,226.39
	(d) Cash and Cash Equivalents	17	482.15	253.50
	(e) Short-Term Loans and Advances	18	1,857.17	757.03
	(f) Other Current Assets	19	269.04	431.70
	<b>Total</b>		<b>9,414.07</b>	<b>7,620.81</b>

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1.2 & 3

The Notes referred to above form an integral part of the Balance Sheet

"As per our report of even date attached"  
For M/S MSNT & Associates  
Chartered Accountants Firm Reg. No. - 018542C

(CA, Navodit Tyagi)  
Partner  
Membership No. - 533375  
Address : A-40, I-Trium, Tower-B, 10th Floor, Sec-62, Noida  
Place: Noida  
Date: 07/09/2023

UDIN: 2353337586XPW06826



For and On Behalf of the Board

(Mr. Amar Singh) Director  
(Asmita Singh) Director

Rajeev Kumar Nain  
CFO & Company Secretary



**Consolidated Financial Statements of Chandan HealthCare Limited**  
**And Its Subsidiaries Indra Diagnostic Centre & Blood Bank Limited, Chandan Diagnostic Limited and Chandan Pharmacy**  
**Limited**

Corp. Off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow 226021  
 Reg Off. Add.: A-15, Vivek Vihar, Phase-1, Delhi-110095  
 CIN: U85110DL2003PLC308206

**Consolidated Statement of Profit and Loss for the year ended 31-Mar-2023**

In ₹ (LAKH)

Particulars	Note No.	1-Apr2022 to 31-Mar-23	1-Apr2021 to 31-Mar2022
I Revenue from Operations	20	13,688.53	11,956.35
II Other Income	21	13.19	35.22
III TOTAL REVENUE (I + II)		13,701.72	11,991.57
IV EXPENSES			
Purchases of Stock-in-Trade	22	5,493.56	5,284.88
Changes in Inventories	23	(410.17)	(74.28)
Employee Benefit Expenses	24	2,546.09	1,856.68
Finance Costs	25	233.06	170.63
Depreciation and Amortization Expenses	26	208.95	196.06
Other Expenses	27	5,126.15	4,674.06
TOTAL EXPENSES		13,200.63	12,037.04
V Profit before Exceptional and Extraordinary Items and Tax (III-IV)		501.09	(45.47)
VI Exceptional Items			
VII Profit before Extraordinary Items and Tax		501.09	(45.47)
VIII Extraordinary Items			
IX Profit Before Tax		501.09	(45.47)
X Tax Expense			
Current Tax		157.8	1.14
Deferred Tax		31.2	
Minority Interest			
XI Profit/(Loss) for the period from Continuing Operations (IX-X)		362.09	(46.91)
XII Profit/(Loss) from Discontinuing Operations			
XIII Tax Expense from Discontinuing Operations			
XIV Profit/(Loss) from Discontinuing Operations (after tax) (XII-XIII)			
XV Profit/(Loss) for the Period (XI+XIV)		362.09	(46.91)
XVI Earnings per Equity Share			
Basic		0.18	(0.00)
Diluted			

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1.2 & 3

The Notes referred to above form an integral part of the Balance Sheet.

"As per our report of even date attached"

For and On behalf of the Board

For M/S MSNT & Associates

Chartered Accountants, Firm Reg. No. D185425

(CA, Navodit Tyagi)

Partner

Membership No. 533375

Address: A-40, I THUM, Tower-B, 10th Floor, Sec-62, Noida

Place: Noida

Date: 02/09/2023

**UDIN: 23533375BQXPNO6826**



(Dr. Amar Singh)

Director

(Asmita Singh)

Director

Rajeev Kumar Nain

CFO & Company Secretary

## Consolidated Notes to Financial Statements

### 1. COMPANY OVERVIEW

The Company is engaged in the business of trading of medicine and providing medical diagnostic services to individuals and corporate.

### 2. Significant Accounting Policies

#### 2.1 Basis Of Preparation

These Consolidated Financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis.

These Consolidated financial statements have been prepared to comply, in all material aspects, with the applicable accounting standards notified under section 211(3C) [Companies ( Accounting Standards) Rules, 2021, as amended] and the other relevant provisions of the Act .

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Group has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

#### 2.2 Use of Estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of Contingent liabilities, at the end of reporting period. Although these estimates are based on management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

#### 2.3 Principles of consolidation

a. The consolidated financial statements relate to the Company and its Subsidiary company (collectively referred herein under as the "Group"). The consolidated financial statements have been prepared on the following basis:

1. In respect of Subsidiary companies, the financial statements have been consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and unrealized profits / losses on intra-group transactions as per Accounting Standard - AS 21 "Consolidated Financial Statements".

2. The excess of cost to the Company of its investment in the Subsidiary is recognized in the financial statements as Goodwill, which is tested for impairment on every balance sheet date. The excess of Company's share of equity and reserves of such entities over the cost of acquisition is treated as Capital Reserve. Amortization of goodwill is confined to goodwill on amalgamation in accordance with the applicable Accounting Standards.

3. The consolidated financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the Company's separate financial statements. However, in case of depreciation and amortization it was not practicable to use uniform accounting policies.

b. The Subsidiary company considered in the consolidated financial statements are:

Sr. No.	Name of the Company	Country of incorporation	% voting power held as at March 31,2022
1	INDRA DIAGNOSTIC CENTRE & BLOOD BANK LIMITED	India	99.99%
2	CHANDAN DIAGNOSTIC LIMITED	India	67.98%
3	CHANDAN PHARMACY LIMITED	India	53.56%

### 2.3 Property, plant and Equipment

Property, Plant and Equipment are shown at cost less accumulated depreciation.

### 2.4 Depreciation and Amortization

Depreciation is provided at the rates prescribed under Income Tax Act 1961 at W.D.V. method for Holding Company and Depreciation is provided on a pro-rata basis on the straight line method ('SLM') over the useful lives of the assets specified in Schedule II of the Companies Act, 2013 for Subsidiary Company.

### 2.5 Leases

Where the holding company is lessee, Leasehold land, which effectively transfer to the company substantially all the risks and benefits incidental to ownership of

the leased item are capitalized at the inception of the lease term at the lower of the fair value of the leased property and present value of minimum lease payments.

## **2.6 Borrowing Cost**

Interest and other costs on borrowed funds including term loan used to finance the acquisition of fixed asset, upto the date assets are ready for use are estimated and capitalized under respective Property, Plant and Equipment and Intangible Assets.

Other interest and costs incurred on borrowed funds are recognized as expense in the year in which they are incurred.

## **2.7 Impairment of Property, Plant and Equipment**

At each Balance Sheet date, the group reviews the carrying amount of its Property, Plant and Equipment and Intangible Assets to determine whether there is any indication that those assets suffered any impairment loss. If any such indication exists, the recoverable amount of the assets is estimated in order to determine the extent of impairment loss. Recoverable amount is the higher of an assets net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the assets or from its disposal are discounted to their present value using a predetermined rate that reflects the current market assessment of time value of money and the risks specific to the asset. Reversal of impairment loss is recognized immediately as income in the statement of profit and loss.

## **2.8 Investments**

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. If an investment is acquired, or partly acquired by the issue of shares or the other securities, the acquisition cost is the fair value of the securities issued. If an investment is acquired in exchange for another asset, the acquisition cost is determined by reference to the fair value of the asset given up or by reference to the fair value of the investment acquired, whichever is more clearly evident.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long term investments are

stated at cost. Provision is made for diminution, other than temporary, in the value of investments, wherever applicable.

On disposal of an investment the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

## **2.9 Inventories**

Inventories are valued as under:

Raw materials- At weighted average cost price.

Stock of finished goods- At cost or net realizable value whichever is lower.

Stock of Power & Fuel & Packing materials-At cost

WIP- At weighted average cost price.

Obsolete, slow moving and defective stocks are identified at the time of physical verification of stocks and where necessary provision is made for such stocks.

## **2.10 Revenue Recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

### **Sale of goods**

Sales include sales value of goods and are net of sales return, discounts, rebate, rate difference and goods & services tax.

### **Income from investments**

Income from investment, other than investment in shares of companies is included, together with related tax deducted at source in the profit and loss account on an accrual basis. Income from investment in shares of companies is recognized on actual basis.

### **Income from security deposits**

Interest accrued on Security Deposits (if any) recognized on actual basis.

## **2.11 Retirement and other employee benefits**

The group's contributions are made to Provident fund as per the Provident Fund Act. ESI as per the ESI Act is accounted for on accrual basis & Leave encashment, Bonus paid, Gratuity paid to retired employees is accounted for on cash basis.

## **2.12 Accounting for Taxes on Income**

Tax expense comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income tax Act, 1961 enacted in India and tax laws prevailing in the respective tax jurisdictions where the company operates. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognized directly in equity is recognized in equity and not in the statement of profit and loss.

Provision for deferred taxation is made using the liabilities method, at the enacted rates of taxation on all timing differences to the extent that it is probable that a liability or asset will crystallize. When there is unabsorbed depreciation or carry forward loss, deferred tax assets are recognized only if there is virtual certainty of realization of such asset. Deferred tax assets/ liabilities are reviewed at each balance sheet date based on development during the year to reassess realization/ liabilities.

## **2.13 Earnings per share**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity shares to the extent that they are entitled to participate in dividends related to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a right share issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share the net profit or loss for the period attributable to equity share holders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

## **2.14 Provisions**

A provision is recognized when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the

obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Where the group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit and loss net of any reimbursement.

### **2.15 Cash & Cash Equivalents**

Cash & Cash equivalents include cash in hand and cash at bank and other short or highly liquid investments with an original maturity of three months or less.

### **3. NOTES ON ACCOUNTS**

The Schedule III of Companies Act 2013 is used for the preparation of financial statements. This has a significant impact on the disclosure and presentation in financial statements. Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classification/disclosure. The balances of Personal Account are subject to confirmation & reconciliation. In the opinion of the management, the current assets, loans & advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the Balance Sheet.

Place: Lucknow  
Date: 02/09/2023



Dr Amar Singh  
(Director)



Asmita Singh  
(Director)



**Chandan HealthCare Limited**  
Notes to and forming part of Balance Sheet as at 31-Mar-2023

In ₹ (LAKH)

**4. Share Capital**

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	Number	Amount	Number	Amount
<b>Authorised</b>				
20,000,000 Equity Shares of Rs 10/- each (Previous Year 20,000,000 Equity Shares of Rs. 10/- each)	20,000,000	2,000.00	20,000,000	2,000.00
<b>Issued</b>				
20,000,000 Equity Shares of Rs 10/- each (Previous Year 20,000,000 Equity Shares of Rs. 10/- each)	20,000,000	2,000.00	20,000,000	2,000.00
<b>Subscribed and Fully Paid</b>				
20,000,000 Equity Shares of Rs 10/- each (Previous Year 20,000,000 Equity Shares of Rs. 10/- each)	20,000,000	2,000.00	20,000,000	2,000.00
<b>TOTAL</b>	<b>20,000,000</b>	<b>2,000.00</b>	<b>20,000,000</b>	<b>2,000.00</b>

**Notes:**

**a) Shares held by each shareholder holding more than 5% shares as on period end.**

Name of shareholder	as at 31-Mar-2023		as at 31-Mar-2022	
	% Held	Shares( Nos)	% Held	Shares( Nos)
AmarAnita Holdings (India) Private Limited	29.22	5,843,000	29.22	5,843,000
Dr Amar Singh	10.60	2,119,860	10.60	2,119,860
Vinay Lamba	7.92	1,584,800	7.92	1,584,800

**b) Reconciliation of opening and closing outstanding no. of shares**

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	Number	Amount	Number	Amount
<b>Equity Shares Subscribed</b>				
Opening Balance	20,000,000	2,000.00	20,000,000	2,000.00
Fresh Issue	-	-	-	-
Bonus	-	-	-	-
Buyback	-	-	-	-
<b>Closing Balance</b>	<b>20,000,000</b>	<b>2,000.00</b>	<b>20,000,000</b>	<b>2,000.00</b>

**5. Reserves and Surplus**

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
<b>Surplus</b>		
<b>Opening Balance</b>		
- CHCL (Holding Company)	260.87	382.38
- IDC (Subsidiary Company)	(64.52)	-
- CDL (Subsidiary Company)	(48.57)	-
- CPL (Subsidiary Company)	10.31	-
(+ / -) Net profit/(Net loss) for the Current Year	362.09	(46.91)
(+ / -) Income Tax Earlier Year(IDC)	(3.16)	-
(+ / -) Income Tax Earlier Year(CDL)	(0.32)	-
(+ / -) Dividend (CHCL)	-	(100.00)
(+ / -) Dividend (CPL)	-	(15.00)
(+ / -) Income Tax -Current Year (CHCL)	-	(1.79)
(+ / -) Misc Expenses (CHCL)	-	(60.59)
(+ / -) Share Premium	-	456.70
(+ / -) Minority Interest	(26.75)	-
<b>Total</b>	<b>489.94</b>	<b>614.80</b>

In ₹ (LAKH)

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	SECURED	UNSECURED	SECURED	UNSECURED
<b>CHCL (Holding Company)</b>				
(a) Bonds/debentures	-	-	-	-
(b) Term loans:				
From Banks	1,038.79	-	668.72	668.72
From Other Parties	-	1,038.79	361.01	361.01
(c) Deferred Payment Liabilities	-	-	-	-
(d) Deposits	-	-	-	-
(e) Loans & Advances from related parties	-	-	-	-
(f) Long Term maturities of finance lease obligations	-	-	-	-
(g) Other loans and advances	-	-	-	-
<b>Total</b>	<b>1,038.79</b>	<b>1,038.79</b>	<b>1,029.73</b>	<b>1,029.73</b>

**Notes****Details of Term Loans relating to long term borrowings**

Particulars	as at 31-Mar-2023		Period of Maturity (Months)	Nature of Security	Rate of Interest (%)	Period of Default (Days)	Amt of Default	(Repayment due in next 12 months) (B)	Long term borrowings (A-B)
	(A)	(B)							
<b>Secured</b>									
IndusInd Bank	270.51	-	36-60	Hypothycation of Assets	-	-	-	109.95	160.56
State Bank of India	427.80	-	36-60	Hypothycation of Assets	-	-	-	119.25	308.55
Yes bank Limited	104.19	-	36-60	Hypothycation of Assets	-	-	-	20.54	83.64
Punjab National Bank	236.30	-	36-60	Hypothycation of Assets	-	-	-	-	236.30
<b>A</b>	<b>1,038.79</b>	<b>-</b>						<b>249.75</b>	<b>789.04</b>
<b>Unsecured</b>									
<b>B</b>	<b>-</b>	<b>-</b>						<b>-</b>	<b>-</b>
<b>Total(A+B)</b>	<b>1,038.79</b>	<b>-</b>						<b>249.75</b>	<b>789.04</b>

FY 2022-23

FY 2021-22

Less: payment due in next 12 months shown under Other

Current Liabilities

Balance as per Balance sheet

249.75

361.01

789.04

668.72

7. Short Term Borrowings

Particulars	as at 31-Mar-2023			as at 31-Mar-2022		
	SECURED	UNSECURED	TOTAL	SECURED	UNSECURED	TOTAL
<b>CHCL (Holding Company)</b>						
(a) Secured Loans repayable on demand:						
From Banks	492.07	-	492.07	507.48	-	507.48
From Other Parties	-	-	-	-	1.38	1.38
(b) Loans & Advances from related parties	342.04	-	342.04	-	-	-
(c) Deposits	-	-	-	-	-	-
(d) Other loans and advances	-	-	-	-	-	-
(e) Current Maturities of Long Term Borrowings	249.75	-	249.75	361.01	-	361.01
<b>A</b>	<b>1,083.85</b>	<b>-</b>	<b>1,083.85</b>	<b>868.50</b>	<b>1.38</b>	<b>869.87</b>
<b>CPL (Subsidiary Company)</b>						
(a) Secured Loans repayable on demand:						
From Banks	478.12	-	478.12	-	-	-
From Other Parties	-	-	-	-	-	-
(b) Loans & Advances from related parties	-	-	-	-	-	-
(c) Deposits	-	-	-	-	-	-
(d) Other loans and advances	-	-	-	-	-	-
(e) Current Maturities of Long Term Borrowings	-	-	-	-	-	-
<b>B</b>	<b>478.12</b>	<b>-</b>	<b>478.12</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total(A+B)</b>	<b>1,561.97</b>	<b>-</b>	<b>1,561.97</b>	<b>868.50</b>	<b>1.38</b>	<b>869.87</b>

Notes-

**Details of Security (Cash Credit Limit):**

1. Prime Security :- Hypothecation of all type of stocks and book debts by way of first charge.
2. Collateral Security :- Equitable Mortgage created by way of Deposit of Title Deed on the immovable property.
3. Personal Guarantee of all the Directors

7. Short Term Borrowings

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	SECURED	UNSECURED	SECURED	UNSECURED
<b>CHCL (Holding Company)</b>				
(a) Secured Loans repayable on demand:				
From Banks	492.07	-	507.48	-
From Other Parties	-	-	-	1.38
(b) Loans & Advances from related parties	342.04	-	-	-
(c) Deposits	-	-	-	-
(d) Other loans and advances	-	-	-	-
(e) Current Maturities of Long Term Borrowings	249.75	-	361.01	-
<b>A</b>	<b>1,083.85</b>	<b>-</b>	<b>868.50</b>	<b>1.38</b>
<b>CPL (Subsidiary Company)</b>				
(a) Secured Loans repayable on demand:				
From Banks	478.12	-	-	-
From Other Parties	-	-	-	-
(b) Loans & Advances from related parties	-	-	-	-
(c) Deposits	-	-	-	-
(d) Other loans and advances	-	-	-	-
(e) Current Maturities of Long Term Borrowings	-	-	-	-
<b>B</b>	<b>478.12</b>	<b>-</b>	<b>478.12</b>	<b>-</b>
<b>Total(A+B)</b>	<b>1,561.97</b>	<b>-</b>	<b>868.50</b>	<b>1.38</b>
				<b>869.87</b>

Notes-

**Details of Security (Cash Credit Limit):**

1. Prime Security :- Hypothecation of all type of stoks and book debts by way of first charge.
2. Collateral Security :- Equitable Mortgage created by way of Deposit of Title Deed on the immovable property.
3. Personal Guarantee of all the Directors

## 8. Trade Payables

Figures For the Current Reporting Period

In ₹ (LAKH)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME (CHCL)	209.02	-	-	-	209.02
MSME (CPL)	216.70	-	-	-	216.70
Others (CHCL)	78.69	-	-	-	78.69
Others (CDL)	-	-	-	-	-
Others (CPL)	240.86	-	-	-	240.86
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
<b>Total</b>					<b>745.28</b>

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME (CHCL)	46.65	-	-	-	46.65
MSME (CPL)	83.78	-	-	-	83.78
Others (CHCL)	731.24	-	-	-	731.24
Others (CDL)	1.93	-	-	-	1.93
Others (CPL)	851.79	-	-	-	851.79
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
<b>Total</b>					<b>1,715.40</b>

**Chandan HealthCare Limited**  
Notes to and forming part of Balance Sheet as at 31-Mar-2023

**9 . Other Current Liabilities**

In ₹ (LAKH)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
<b>CHCL (Holding Company)</b>		
Current Maturities of Finance Lease Obligations	-	-
Interest Accrued but not due on Borrowings	-	-
Interest Accrued and due on Borrowings	-	-
Income Received in Advance	-	-
Unpaid Dividends	-	-
Application money received for allotment of securities and due for refund and interest accrued thereon	-	-
Unpaid matured Deposits and Interest accrued thereon	-	-
Unpaid matured Debentures and Interest accrued thereon	-	-
<b>Other Payables :</b>	-	-
- Statutory Remittances	37.68	69.73
- GST Payable	-	4.61
- Fixed Assets Creditors	147.59	28.09
- Commission Payable	48.91	41.81
- Payable to Staff	106.59	85.96
- Cheque Issued But Not Cleared	4.14	351.78
- Security(Franchisee)	0.65	0.35
- Creditors -Maintenance	162.76	188.11
- Reimbursement Payable	6.43	22.84
- Creditors -Rent	5.08	4.50
- Payable to Professional	18.45	0.87
- Creditors -Expenses	835.82	1.45
- Other Creditors	368.14	172.47
<b>A</b>	<b>1,742.24</b>	<b>972.56</b>
<b>IDC (Subsidiary Company)</b>		
<b>Other Payables :</b>		
- Payable to Staff	-	9.53
- Cheque Issued But Not Cleared	27.74	2.55
- TDS Payable	-	4.45
- Gratuity Payable	95.02	-
- Payable to Professionals	0.30	0.36
- Other Creditors	-	1.17
- Advance from Parties	0.77	-
- Other Misc Payables	59.09	67.40
<b>B</b>	<b>182.93</b>	<b>85.47</b>
<b>CDL (Subsidiary Company)</b>		
<b>Other Payables :</b>		
- Audit Fees Payable	0.47	0.35
- Creditors for Expenses	37.56	58.27
- Cheque Issued but not Cleared	-	-
<b>C</b>	<b>38.03</b>	<b>58.62</b>
<b>CPL (Subsidiary Company)</b>		
<b>Other Payables :</b>		
- Creditors for Expenses	419.36	134.54
- Creditors for Rent	0.82	0.18
- Creditors for Fixed Assets	1.53	0.21
- Cheque Issued But Not Cleared	797.75	20.00
- Payable to Professionals	28.28	0.27
- Payable to Staff	53.28	-
- Commission Payable	6.04	-
- Other Payable	-	13.45
<b>D</b>	<b>1,307.07</b>	<b>168.64</b>
<b>Total (A+B+C+D)</b>	<b>3,270.27</b>	<b>1,285.30</b>

**10. Short Term Provision**

In ₹ (LAKH)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
<b>CHCL (Holding Company)</b>		
(a) Provision for Employee Benefits	318.76	282.59
(b) Others (specify nature)		
- TDS Interest Payable	-	0.22
<b>CPL (Subsidiary Company)</b>		
(a) Provision for Employee Benefits	12.94	37.66
(b) Others (specify nature)		
- Audit Fees Payable	-	0.87
- GST Payable	3.21	
- Income Tax Payable	20.89	9.65
- Statutory Payable	11.99	3.88
<b>Total</b>	<b>367.78</b>	<b>334.88</b>

**12. Non-Current Investments**

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Investment property		-
(b) Investments in Equity Instruments		
CHCL (Holding Company)	509.14	837.08
IDC (Subsidiary Company)	47.40	47.40
CDL (Subsidiary Company)	37.40	37.40
CPL (Subsidiary Company)	114.75	114.75
(c) Investments in preference shares	-	-
(d) Investments in Government or trust securities	-	-
(e) Investments in debentures or bonds	-	-
(f) Investments in Mutual Funds	-	-
(g) Investments in partnership firms	-	-
(h) Other non-current investments (specify nature)	-	-
<b>Total</b>	<b>708.68</b>	<b>1,036.63</b>

**13. Long Term Loans & Advances**

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Capital Advances - CHCL	-	-
(b) Loans and Advances to Related Parties - CPL	715.55	117.71
(c) Other loans and advances (specify nature)		
Secured, considered good;		
- Income Tax Refundable - CHCL	115.17	86.63
- MAT Credit -CDL	0.58	0.70
- Loan & Advance to Employee - CPL	5.34	2.78
<b>Total</b>	<b>836.64</b>	<b>207.82</b>

**14. Other Non-Current Assets**

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Security Deposits		
CHCL (Holding Company)	54.98	48.62
IDC (Subsidiary Company)	2.01	2.16
CPL (Subsidiary Company)	7.37	4.00
(b) Other (specify nature)	-	-
Secured, considered good;		
<b>Total</b>	<b>64.35</b>	<b>54.78</b>

15 . Inventories		In ₹ (LAKH)	
Particulars	as at 31-Mar-2023	as at 31-Mar-2022	
(a) Raw Materials	-	-	
(b) Work-in-progress	-	-	
(c) Finished goods	-	-	
(d) Stock-in-trade	-	-	
<b>CHCL (Holding Company)</b>	35.81	123.03	
<b>CPL (Subsidiary Company)</b>	951.31	533.00	
(e) Stores and spares	-	-	
(f) Loose tools	-	-	
(g) Others (specify nature)	-	-	
	-	-	
<b>Total</b>	<b>987.12</b>	<b>656.03</b>	

#### 17 . Cash and Cash Equivalents

Particulars	as at 31-Mar-2023	as at 31-Mar-2022	
<b>(a) Balances with banks</b>			
Earmarked Balances		-	
In Current Account			
<b>CHCL (Holding Company)</b>	25.06	31.47	
<b>IDC (Subsidiary Company)</b>	6.83	8.69	
<b>CDL (Subsidiary Company)</b>	0.30	0.08	
<b>CPL (Subsidiary Company)</b>	28.65	1.26	
Margin Money			
<b>CHCL (Holding Company)</b>	-	124.03	
<b>IDC (Subsidiary Company)</b>	4.25	4.03	
Security Against Borrowings		-	
Guarantees		-	
Other Commitments ( Security/earnest money)		-	
Bank deposits with more than 12 months maturity		-	
<b>CHCL (Holding Company)</b>	309.49		
<b>(b) Cheques, drafts on hand</b>		-	
<b>(c) Cash on hand</b>			
<b>CHCL (Holding Company)</b>	97.27	40.82	
<b>IDC (Subsidiary Company)</b>	0.41	0.60	
<b>CDL (Subsidiary Company)</b>	2.93	14.98	
<b>CPL (Subsidiary Company)</b>	6.97	27.55	
<b>(d) Others</b>	-	-	
	-	-	
<b>Total</b>	<b>482.15</b>	<b>253.50</b>	



## 18 . Short Term Loans and Advances

In ₹ (LAKH)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
<b>(a)Loans and Advances to Related Parties</b>		
CHCL (Holding Company)	-	-
IDC (Subsidiary Company)	378.83	341.83
CDL (Subsidiary Company)	43.49	54.22
<b>(b)Other Loans and Advances</b>		
Unsecured, considered good	-	-
<b>CHCL (Holding Company)</b>		
- Goods & Service Tax	13.18	-
- Advance for Expenses	20.57	20.25
- Loan and Advance to Staff	68.06	65.16
- Advance for Fixed Assets	316.53	39.88
- Advance Tax	7.92	-
- Other Misc Advance	-	0.70
<b>IDC (Subsidiary Company)</b>		
- Advance to Staff	-	0.08
- Advance Tax -TDS Earlier Year	4.29	7.50
- Amount Received against Card	-	0.04
- Cheques Presented But Not Cleared	27.74	-
- MAT Credit Entitlement	5.92	5.92
<b>CDL (Subsidiary Company)</b>		
- Income Tax Refundable	0.07	0.44
- Other Advance	0.03	0.03
<b>CPL (Subsidiary Company)</b>		
- Goods & Service Tax	-	9.06
- Advance for Expenses	4.22	3.06
- Advance to Supplier	29.43	3.46
- Advance for Fixed Assets	0.30	1.38
- Advance Tax	0.11	0.11
- Sundry Debtors	751.23	198.91
- Other Misc Advance	185.25	-
<b>Total</b>	<b>1,857.17</b>	<b>752.03</b>

## 19 . Other Current Assets

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
<b>CHCL (Holding Company)</b>		
- Goods & Service Tax	-	-
- Interest Accrued on Bank Deposit	11.08	7.24
- Receivable against Investment Sold	-	423.58
- Cheque Presented But Not Cleared	242.24	-
- Amount Received against Card	6.73	0.89
<b>Total</b>	<b>260.04</b>	<b>431.70</b>

SCHEDULE -11

CHCL Schedule Of Fixed Assets & Depreciation as per Companies Act 1956  
For the Year ended 31st March 2023

In ₹ (LAKH)

Sno.	ASSETS	GROSS BLOCK						DEPRECIATION						WDV AS ON	
		AS ON 1/4/2022	ADDITIONS DURING THE YEAR	ADJ.	AS ON 31/03/23	AS ON 1/4/2022	Dep on Opening	Dep on Addition	DURING THE YEAR	ADJ.	Assets Life	TOTAL	AS ON 31/03/23	AS ON 31/03/22	
<b>CHCL (Holding Company)</b>															
1	Computers	335.98	33.37	5.00	364.35	267.72	21.33	3.31	24.63	0.46	3 Year	291.89	72.45	58.27	
2	Electric Installation	68.02	3.00	-	71.02	53.60	1.44	0.13	1.57	-	10 Year	55.17	15.85	14.41	
3	Furniture & Fixtures	105.93	13.42	-	119.35	90.09	1.58	0.84	2.42	-	10 Year	92.52	26.83	15.84	
4	Office Interior & Renovation	362.87	15.68	-	378.55	290.09	1.21	0.08	1.29	-	60 Year	291.39	87.17	72.77	
5	Plant & Machinery	3,815.62	402.21	-	4,217.83	1,876.34	149.18	10.24	159.41	-	13 Year	2,035.75	2,182.08	1,939.28	
6	Building Leasehold	309.13	-	-	309.13	76.73	3.87	-	3.87	-	60 Year	80.61	228.52	232.39	
7	Office Equipment	220.72	26.05	-	246.77	87.90	10.22	0.86	11.08	-	13 Year	98.97	147.80	132.83	
8	Vehicles	80.03	8.42	-	88.45	74.83	0.87	0.31	1.18	-	6 Years	76.01	12.45	5.20	
	<b>TOTAL</b>	<b>5,298.30</b>	<b>502.15</b>	<b>5.00</b>	<b>5,795.45</b>	<b>2,817.31</b>	<b>189.70</b>	<b>15.76</b>	<b>205.46</b>	<b>0.46</b>		<b>3,022.31</b>	<b>2,773.14</b>	<b>2,480.99</b>	
12	Intangible Assets Under Development														
13	Capital Work-in-progress : Building														
	<b>TOTAL CHCL</b>	<b>5,298.30</b>	<b>502.15</b>	<b>5.00</b>	<b>5,795.45</b>	<b>2,817.31</b>	<b>189.70</b>	<b>15.76</b>	<b>205.46</b>	<b>0.46</b>		<b>3,022.31</b>	<b>2,773.14</b>	<b>2,480.99</b>	
<b>IDC (Subsidiary Company)</b>															
1	Electrical Installations	22.51			22.51	22.16					10 Year	22.16	0.35	0.35	
2	Furniture & Fixture	7.58			7.58	7.51					10 Year	7.51	0.07	0.07	
3	Plant & Machinery	174.68			174.68	174.65					13 Year	174.65	0.03	0.03	
	<b>TOTAL IDC</b>	<b>204.78</b>			<b>204.78</b>	<b>204.32</b>						<b>204.32</b>	<b>0.46</b>	<b>0.46</b>	
<b>CDL (Subsidiary Company)</b>															
1	Freehold Building	1.00			1.00								1.00	1.00	
	<b>TOTAL IDC</b>	<b>1.00</b>			<b>1.00</b>								<b>1.00</b>	<b>1.00</b>	
<b>CPL (Subsidiary Company)</b>															
	Computers	4.35	0.22		4.57	3.78			0.03			3.80	0.77	0.58	
	Office Equipment	2.34	4.35		6.69	1.58			0.86			2.45	4.25	0.76	
	Furniture & Fixtures	7.66	8.44		16.11	1.36			1.05		2.40	13.71	6.31		
	Office Interior & Renovation	3.59	15.98		19.56	0.34			1.51		1.85	17.71	3.25		
	Electric Installations	-	1.25		1.25	-			0.04		0.04	1.21	-		
	Plant and Machinery (medical)	-	0.09		0.09	-			0.01		0.01	0.09	-		
	<b>TOTAL IDC</b>	<b>17.95</b>	<b>30.33</b>		<b>48.28</b>	<b>7.06</b>			<b>3.49</b>			<b>10.55</b>	<b>37.73</b>	<b>10.89</b>	
	<b>GRAND TOTAL</b>	<b>5,522.03</b>	<b>532.48</b>	<b>5.00</b>	<b>6,049.51</b>	<b>3,028.69</b>	<b>189.70</b>	<b>15.76</b>	<b>208.95</b>	<b>0.46</b>		<b>3,237.18</b>	<b>2,812.33</b>	<b>2,493.34</b>	

**16. Trade Receivable**

**Figures For the Current Reporting Period**

In ₹ (LAKH)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods						
CHCL	1,396.64	-	-	-	-	1,396.64
IDC	-	-	-	-	-	-
CPL	0.36	-	-	-	-	0.36
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
<b>Total</b>	<b>1,397.00</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,397.00</b>

**Figures For Previous Reporting Period**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods						
CHCL	1,044.38	-	-	-	-	1,044.38
IDC	54.34	-	-	-	-	54.34
CPL	627.67	-	-	-	-	627.67
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
<b>Total</b>	<b>1,726.39</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,726.39</b>

Chandan HealthCare Limited

Notes to and forming part of Statement of Profit and Loss for the year ended 31-Mar-2023

20. Revenue From Operations

In ₹ (LAKH)

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
Sales of Product	235.41	1,360.37	1,327.46
Sales of Services	7,347.52	5,800.04	4,267.39
<b>A</b>	<b>7,582.93</b>	<b>7,160.41</b>	<b>5,594.85</b>
<b>IDC (Subsidiary Company)</b>			
Sales of Product	-	-	-
Sales of Services	197.91	349.15	247.02
<b>B</b>	<b>197.91</b>	<b>349.15</b>	<b>247.02</b>
<b>CDL (Subsidiary Company)</b>			
Sales of Product	-	-	-
Sales of Services	-	-	-
<b>C</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>CPL (Subsidiary Company)</b>			
Sales of Product	5,907.69	4,446.79	2,874.42
Sales of Services	-	-	-
<b>D</b>	<b>5,907.69</b>	<b>4,446.79</b>	<b>2,874.42</b>
<b>Total (A+B+C+D)</b>	<b>13,688.53</b>	<b>11,956.35</b>	<b>8,716.29</b>

21 . Other Income

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
Interest Income	7.75	5.86	0.90
Dividend Income	-	-	-
Net gain/loss on sale of investments	-	7.16	-
Other Non-Operating Income	0.56	7.25	7.24
<b>A</b>	<b>8.31</b>	<b>20.26</b>	<b>8.14</b>
<b>IDC (Subsidiary Company)</b>			
Interest Income	0.29	1.53	0.28
Other Non-Operating Income	0.01	4.99	1.71
<b>B</b>	<b>0.30</b>	<b>6.52</b>	<b>1.99</b>
<b>CDL (Subsidiary Company)</b>			
Other Non-Operating Income	2.41	6.18	5.04
<b>C</b>	<b>2.41</b>	<b>6.18</b>	<b>5.04</b>
<b>CPL (Subsidiary Company)</b>			
Other Non-Operating Income	2.17	2.27	8.20
<b>D</b>	<b>2.17</b>	<b>2.27</b>	<b>8.20</b>
<b>Total (A+B+C+D)</b>	<b>13.19</b>	<b>35.22</b>	<b>23.37</b>

22 . Purchases of Stock in Trade

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
Purchases of medicine	163.41	1,101.88	1,244.54
<b>CPL (Subsidiary Company)</b>			
Purchases of medicine	5,330	4,183.00	2,744.69
<b>Total</b>	<b>5,493.56</b>	<b>5,284.88</b>	<b>3,989.23</b>

## 23. Change in Inventories

In ₹ (LAKH)

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
Opening Balance	43.96	160.22	174.64
Less Closing Balance	35.81	43.96	160.22
<b>A</b>	<b>8.15</b>	<b>116.26</b>	<b>14.42</b>
<b>CPL (Subsidiary Company)</b>			
Opening Balance	533.00	342.46	237.01
Less Closing Balance	951.31	533.00	342.46
<b>B</b>	<b>(418.32)</b>	<b>(190.54)</b>	<b>(105.44)</b>
<b>Total (A+B)</b>	<b>(410.17)</b>	<b>(74.28)</b>	<b>(91.02)</b>

## 24. Employee Benefit Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
Salary & Wages	1,794.57	1,317.97	1,019.05
Contribution to PF & Other Funds	145.10	39.40	28.31
Staff Welfare Expenses (Bonus etc.)	27.56	69.84	74.79
<b>A</b>	<b>1,967.23</b>	<b>1,427.20</b>	<b>1,122.15</b>
<b>IDC (Subsidiary Company)</b>			
Salary & Wages	76.24	158.56	133.43
Staff Welfare Expenses (Bonus etc.)	180.84	-	-
<b>B</b>	<b>257.08</b>	<b>158.56</b>	<b>133.43</b>
<b>CDL (Subsidiary Company)</b>			
Salary & Wages	-	-	-
<b>C</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>CPL (Subsidiary Company)</b>			
Salary & Wages	301.57	182.02	119.55
Contribution to PF & Other Funds	8.49	8.55	10.69
Staff Welfare Expenses (Bonus etc.)	14.71	9.35	21.06
<b>D</b>	<b>324.77</b>	<b>199.92</b>	<b>151.30</b>
<b>Total (A+B+C+D)</b>	<b>2,549.09</b>	<b>1,785.68</b>	<b>1,406.88</b>

## 25 . Finance Costs

In ₹ (LAKH)

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
- Interest	152.52	159.87	189.52
- Loan Processing Charges	5.82	1.07	-
- Bank Charges	41.17	7.79	11.02
<b>A</b>	<b>199.51</b>	<b>168.74</b>	<b>200.54</b>
<b>IDC (Subsidiary Company)</b>			
- Bank Charges	0.63	0.81	0.22
<b>B</b>	<b>0.63</b>	<b>0.81</b>	<b>0.22</b>
<b>CPL (Subsidiary Company)</b>			
- Interest	27.67	-	-
- Loan Processing Charges	4.14	-	-
- Bank Charges	1.12	1.08	1.22
<b>C</b>	<b>32.92</b>	<b>1.08</b>	<b>1.22</b>
<b>Total (A+B+C)</b>	<b>233.06</b>	<b>170.63</b>	<b>201.98</b>

## 26. Depreciation and Amortization Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Depreciation	208.95	196.06	155.88
<b>Total</b>	<b>208.95</b>	<b>196.06</b>	<b>155.88</b>

## 27. Other Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
<b>CHCL (Holding Company)</b>			
<b>Payment to Auditors</b>			
As Auditor	0.50	0.60	0.30
<b>Consumption of stores and spare parts</b>	<b>1,370.42</b>	<b>956.96</b>	<b>665.19</b>
<b>Power &amp; Fuel</b>	<b>167.95</b>	<b>139.91</b>	<b>119.76</b>
<b>Rent</b>	<b>245.33</b>	<b>261.40</b>	<b>198.65</b>
<b>Repairs to machinery</b>	<b>129.47</b>	<b>8.13</b>	<b>7.20</b>
<b>Repairs to Building</b>	<b>16.71</b>	<b>82.26</b>	<b>102.49</b>
<b>Insurance</b>	<b>3.92</b>	<b>3.18</b>	<b>2.42</b>
<b>Miscellaneous expenses</b>			
- Travelling and Conveyance Expenses	695.77	770.45	425.95
- Professional Fees to Doctors / Technicians	-	901.31	711.68
- Pathological Test Expenses	35.01	21.89	34.69
- General Expenses	2.72	2.41	3.55
- Rates & Taxes	13.35	10.64	2.95
- Professional Fees to Consultants	1,012.91	8.36	0.55
- Business Promostion Exp	20.20	21.72	1.37
- Telephone & Internet Exp	20.43	21.81	25.81
- Bank Charges	8.84	-	-
- Maintenance Others	19.19	-	-

- Consumable Damage	-	-	244.77
- Staff Welfare Expenses	-	26.42	8.26
- Penal Interest & Fees	9.46	63.62	-
- TPA Charges	-	2.11	6.16
- Waste Management	-	5.19	4.20
- Commission Expenses	489.13	-	-
- Software Expenses	7.96	1.64	11.56
- Filing Expenses	1.15	1.86	0.34
- Quality Expenses	2.72	4.41	0.18
- Postal & Courier Expenses	10.34	10.05	6.71
- GST Expenses	43.20	20.59	27.18
- Bad Debts	3.89	480.49	8.27
- Freight and Forwarding	-	0.89	1.26
- Books, Periodicals & Certifications	2.55	-	-
- Other Misc Exp	187.78	414.50	97.85
<b>A</b>	<b>4,520.90</b>	<b>4,242.80</b>	<b>2,719.28</b>
<b>IDC (Subsidiary Company)</b>			
<b>Payment to Auditors</b>			
As Auditor	0.10	0.17	0.20
For Taxation Matter	-	0.08	0.10
<b>Consumption of stores and spare parts</b>	<b>7.51</b>	<b>9.51</b>	<b>10.64</b>
<b>Power &amp; Fuel</b>	<b>5.78</b>	<b>9.36</b>	<b>8.65</b>
<b>Rent</b>	<b>4.26</b>	<b>5.11</b>	<b>4.69</b>
<b>Repairs to machinery</b>	<b>0.16</b>	<b>0.17</b>	<b>0.44</b>
<b>Repairs to Building</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Insurance</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Miscellaneous expenses</b>			
- Professional Fees Expenses	7.50	24.92	52.99
- TPA Charge	-	-	1.83
- Tour & Travel Expenses	0.73	61.90	4.21
- Telephone & Internet Expenses	0.10	0.16	0.17
- ROC & Compliance Expenses	0.02	0.03	0.06
- Pathological Testing Fee	-	57.65	42.21
- Other Mic Exp	3.55	6.96	4.50
<b>B</b>	<b>29.71</b>	<b>176.01</b>	<b>130.67</b>
<b>CDL (Subsidiary Company)</b>			
<b>Payment to Auditors</b>			
As Auditor	0.13	0.12	0.24
<b>Consumption of stores and spare parts</b>	<b>-</b>	<b>-</b>	<b>0.04</b>
<b>Miscellaneous expenses</b>			
- House Tax	0.30	0.30	0.30
- Tour and Travelling Expenses	2.05	4.35	-
- Professional Fees	-	-	9.80
- Other Mic Exp	0.14	0.19	0.29
<b>C</b>	<b>2.61</b>	<b>4.96</b>	<b>10.66</b>
<b>CPL (Subsidiary Company)</b>			
<b>Payment to Auditors</b>			
As Auditor	0.40	0.25	0.56
<b>Consumption of stores and spare parts</b>	<b>10.07</b>	<b>4.94</b>	<b>1.29</b>
<b>Power &amp; Fuel</b>	<b>3.98</b>	<b>0.10</b>	<b>0.10</b>
<b>Rent</b>	<b>84.29</b>	<b>37.06</b>	<b>10.91</b>
<b>Repairs to machinery</b>	<b>0.88</b>	<b>0.49</b>	<b>0.08</b>
<b>Repairs to Building</b>	<b>14.23</b>	<b>2.08</b>	<b>1.95</b>
<b>Insurance</b>	<b>1.64</b>	<b>0.37</b>	<b>-</b>
<b>Miscellaneous expenses</b>			
- Professional Fees	32.07	4.24	21.45
- Travelling & Conveyance Exp	311.85	182.84	0.11
- Commission Exp	80.09	14.26	6.03
- ROC & Compliance Exp	0.08	0.06	0.03
- Sales and Promotion Expenses	9.98	-	-
- Legal Expenses	2.94	-	-
- Other Mic Exp	20.41	3.59	7.37
<b>D</b>	<b>572.93</b>	<b>250.29</b>	<b>49.88</b>
<b>Total (A+B+C+D)</b>	<b>5,126.15</b>	<b>4,674.06</b>	<b>2,910.49</b>